Published in Front Neurol on July 01, 2013
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Distinct Neurodegenerative Changes in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia Linked to Mutant TAU Protein. Stem Cell Reports (2015) 0.89
Acetylation: a new key to unlock tau's role in neurodegeneration. Alzheimers Res Ther (2014) 0.86
Tau phosphorylation at serine 396 residue is required for hippocampal LTD. J Neurosci (2015) 0.83
Clinical perspectives of TRAIL: insights into central nervous system disorders. Cell Mol Life Sci (2016) 0.81
Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? Oxid Med Cell Longev (2015) 0.80
Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain. Acta Neuropathol Commun (2016) 0.80
Epidemiological pathology of Tau in the ageing brain: application of staging for neuropil threads (BrainNet Europe protocol) to the MRC cognitive function and ageing brain study. Acta Neuropathol Commun (2016) 0.80
Roles of tau protein in health and disease. Acta Neuropathol (2017) 0.80
Ameliorative Effects of Antioxidants on the Hippocampal Accumulation of Pathologic Tau in a Rat Model of Blast-Induced Traumatic Brain Injury. Oxid Med Cell Longev (2015) 0.78
Alzheimer disease: modeling an Aβ-centered biological network. Mol Psychiatry (2016) 0.78
Derailed intraneuronal signalling drives pathogenesis in sporadic and familial Alzheimer's disease. Biomed Res Int (2014) 0.76
Astrocyte pathology in a human neural stem cell model of frontotemporal dementia caused by mutant TAU protein. Sci Rep (2017) 0.76
Role of tau in the spatial organization of axonal microtubules: keeping parallel microtubules evenly distributed despite macromolecular crowding. Cell Mol Life Sci (2016) 0.76
Cornel Iridoid Glycoside Attenuates Tau Hyperphosphorylation by Inhibition of PP2A Demethylation. Evid Based Complement Alternat Med (2013) 0.76
"Tau oligomers," what we know and what we don't know. Front Neurol (2014) 0.76
Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2. J Neurosci Res (2015) 0.75
The neurotoxicity of amyloid β-protein oligomers is reversible in a primary neuron model. Mol Brain (2017) 0.75
Tau phosphorylation induced by severe closed head traumatic brain injury is linked to the cellular prion protein. Acta Neuropathol Commun (2017) 0.75
mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. Alzheimers Dement (2016) 0.75
Glycan Determinants of Heparin-Tau Interaction. Biophys J (2017) 0.75
Integrated analysis of differential gene expression profiles in hippocampi to identify candidate genes involved in Alzheimer's disease. Mol Med Rep (2015) 0.75
Imaging pathological tau in atypical parkinsonian disorders. Curr Opin Neurol (2015) 0.75
Imaging tau pathology in Parkinsonisms. NPJ Parkinsons Dis (2017) 0.75
Inhibition of glycogen synthase kinase-3 by BTA-EG4 reduces tau abnormalities in an organotypic brain slice culture model of Alzheimer's disease. Sci Rep (2017) 0.75
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 7.52
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
Propagation of tau pathology in a model of early Alzheimer's disease. Neuron (2012) 6.23
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem (2009) 5.76
Trans-synaptic spread of tau pathology in vivo. PLoS One (2012) 4.53
Differential regulation of dynein and kinesin motor proteins by tau. Science (2008) 4.29
Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci (2008) 4.09
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature (1999) 3.96
Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 3.85
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol (2011) 3.69
Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol (1998) 3.53
Caspase activation precedes and leads to tangles. Nature (2010) 3.24
Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22
Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron (2003) 2.97
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A (2001) 2.97
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett (1992) 2.85
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell (2000) 2.77
Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron (2010) 2.68
Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci (2010) 2.66
Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci (2007) 2.55
Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med (1996) 2.46
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med (2009) 2.39
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2.39
Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci (2005) 2.35
Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. J Cell Biol (1995) 2.29
Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry (2011) 2.20
Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging (2003) 2.19
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol Biol Cell (1995) 2.15
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem (1995) 2.09
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. FEBS Lett (1996) 1.90
Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry (1999) 1.88
Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci (2004) 1.88
Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta (2005) 1.82
JNK3 perpetuates metabolic stress induced by Aβ peptides. Neuron (2012) 1.80
Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol (1994) 1.80
The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem (2011) 1.80
GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry (2004) 1.79
Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79
Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett (1993) 1.74
Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging (2004) 1.73
The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci (2005) 1.72
A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J (2004) 1.71
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 1.70
New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem (1998) 1.69
Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem (2007) 1.68
Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener (2011) 1.67
Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A (2008) 1.64
Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem (2002) 1.62
Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol (2002) 1.61
The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci (2012) 1.60
Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron (2012) 1.58
Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep (2013) 1.57
Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochem Int (2011) 1.56
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A (2006) 1.52
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells. Mol Cell Neurosci (2007) 1.50
Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci (2004) 1.48
Nuclear tau, a key player in neuronal DNA protection. J Biol Chem (2010) 1.47
Cdk5/p35 phosphorylates lemur tyrosine kinase-2 to regulate protein phosphatase-1C phosphorylation and activity. J Neurochem (2012) 1.47
Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J Neurosci (2002) 1.46
The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation. Neuron (2013) 1.43
A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis (2009) 1.42
Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem (2004) 1.40
Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J Neurochem (2006) 1.39
Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem (2008) 1.38
Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell (2007) 1.37
The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem (2007) 1.37
The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol (2012) 1.36
Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci (2005) 1.35
Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol (2009) 1.35
Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A (2006) 1.33
Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: the effects on the organization and stability of microtubules. Neuroscience (1996) 1.33
Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. J Neurochem (1999) 1.33
Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J (2011) 1.32
Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am J Pathol (2011) 1.30
Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol (2002) 1.30
Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis (2011) 1.27
Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol (2003) 1.24
Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J (2007) 1.24
A novel transmembrane Ser/Thr kinase complexes with protein phosphatase-1 and inhibitor-2. J Biol Chem (2002) 1.24
Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J Biol Chem (2009) 1.23
Selective stabilization of tau in axons and microtubule-associated protein 2C in cell bodies and dendrites contributes to polarized localization of cytoskeletal proteins in mature neurons. J Cell Biol (1996) 1.22
Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem (2000) 1.22
Biology of mitochondria in neurodegenerative diseases. Prog Mol Biol Transl Sci (2012) 1.22
Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J Biol Chem (2009) 1.21
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 1.21
Molecular motors implicated in the axonal transport of tau and alpha-synuclein. J Cell Sci (2005) 1.20
Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis (2012) 1.20
Visualization of translated tau protein in the axons of neuronal P19 cells and characterization of tau RNP granules. J Cell Sci (2002) 1.19
AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid β-peptide exposure. Biochem J (2011) 1.18
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci (2008) 4.09
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol (2012) 3.31
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry (2009) 3.15
Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet (2007) 2.73
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr (2004) 2.54
The dementias. Lancet (2002) 2.42
A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet (2005) 2.04
Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A (2004) 1.95
Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci (2002) 1.83
Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet (2002) 1.77
Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann Neurol (2008) 1.74
DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet (2006) 1.73
Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis (2010) 1.73
The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet (2012) 1.71
Direct evidence for axonal transport defects in a novel mouse model of mutant spastin-induced hereditary spastic paraplegia (HSP) and human HSP patients. J Neurochem (2009) 1.61
SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet (2010) 1.58
Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep (2013) 1.57
The FE65 proteins and Alzheimer's disease. J Neurosci Res (2008) 1.51
Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50
Neurofilaments and neurological disease. Bioessays (2003) 1.50
SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis (2007) 1.49
Cdk5/p35 phosphorylates lemur tyrosine kinase-2 to regulate protein phosphatase-1C phosphorylation and activity. J Neurochem (2012) 1.47
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage (2010) 1.44
Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem (2008) 1.38
Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol (2012) 1.36
Parkinson's disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J Cell Sci (2004) 1.36
The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry (2011) 1.35
Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J Neurosci (2005) 1.35
Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neuroimage (2011) 1.34
Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology (2004) 1.32
Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage (2011) 1.30
Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis (2014) 1.29
Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun (2009) 1.28
MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci (2009) 1.28
The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. J Biol Chem (2003) 1.27
Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing (2003) 1.26
Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol (2010) 1.26
Alpha-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. Neuromolecular Med (2004) 1.26
AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage (2011) 1.24
Neurofilament heavy chain side arm phosphorylation regulates axonal transport of neurofilaments. J Cell Biol (2003) 1.24
Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. FASEB J (2007) 1.24
Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry (2010) 1.24
Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet (2010) 1.23
Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2005) 1.22
A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology (2013) 1.21
Molecular motors implicated in the axonal transport of tau and alpha-synuclein. J Cell Sci (2005) 1.20
Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem (2007) 1.20
VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis. Hum Mol Genet (2011) 1.19
Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J Neuropathol Exp Neurol (2002) 1.16
Charcot-Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport. Hum Mol Genet (2002) 1.16
Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. Hum Mol Genet (2007) 1.16
Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc (2006) 1.15
The X11/Mint family of adaptor proteins. Brain Res Rev (2006) 1.14
Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging (2011) 1.13
Effect of APOE ε4 allele on cortical thicknesses and volumes: the AddNeuroMed study. J Alzheimers Dis (2010) 1.12
The neuronal adaptor protein X11beta reduces amyloid beta-protein levels and amyloid plaque formation in the brains of transgenic mice. J Biol Chem (2004) 1.12
Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med (2010) 1.12
Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. Eur J Neurosci (2008) 1.12
Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging (2013) 1.12
Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. J Alzheimers Dis (2012) 1.11
Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol (2008) 1.11
Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J (2008) 1.11
Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS One (2011) 1.10
Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groups--the AddNeuroMed study. Neurobiol Aging (2009) 1.09
Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study. Neurosci Lett (2004) 1.09
Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J (2008) 1.08
p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett (2007) 1.08
Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging (2010) 1.08
A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: Evaluation of a novel lateral ventricle segmentation method. Neuroimage (2011) 1.06
The c-Abl tyrosine kinase phosphorylates the Fe65 adaptor protein to stimulate Fe65/amyloid precursor protein nuclear signaling. J Biol Chem (2004) 1.06
Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One (2011) 1.06
A blood gene expression marker of early Alzheimer's disease. J Alzheimers Dis (2013) 1.05
Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. Psychiatry Res (2013) 1.05
A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry (2008) 1.04
p38alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol Cell Neurosci (2004) 1.04
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett (2005) 1.04
Complement activation as a biomarker for Alzheimer's disease. Immunobiology (2011) 1.04
Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Hum Mol Genet (2007) 1.03
Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria. Hum Mol Genet (2012) 1.03
Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front Psychiatry (2010) 1.03
Alzheimer risk variant CLU and brain function during aging. Biol Psychiatry (2012) 1.02
BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J Biol Chem (2005) 1.02
Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates Aβ production. Hum Mol Genet (2012) 1.02
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02
Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet (2012) 1.02
The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology (2003) 1.01
Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease. J Alzheimers Dis (2013) 1.01
Tau phosphorylation affects its axonal transport and degradation. Neurobiol Aging (2013) 1.00
Phosphorylation of kinesin light chain 1 at serine 460 modulates binding and trafficking of calsyntenin-1. J Cell Sci (2011) 1.00
Identification of a novel, membrane-associated neuronal kinase, cyclin-dependent kinase 5/p35-regulated kinase. J Neurosci (2003) 1.00
APOE ε2 allele is associated with larger regional cortical thicknesses and volumes. Dement Geriatr Cogn Disord (2010) 1.00
Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse. Neurobiol Aging (2011) 0.99